TransMedics Group is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across various disease states. Co. has developed the Organ Care System (OCS), a portable organ perfusion and monitoring system that using Co.'s technology to replicate near-physiologic conditions for donor organs outside of the human body. The OCS was designed to perfuse donor organs with warm, oxygenated and nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. Co.'s OCS products are one for each of lung, heart and liver transplantations. The TMDX average annual return since 2019 is shown above.
The Average Annual Return on the TMDX average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TMDX average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TMDX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|